Despite the looming crises, Novartis will be shutting down antimicrobial research at its Novartis Institutes for Biomedical Research campus in Emeryville, California. There will be a loss of 140 jobs and the current projects will be put up for sale. This company was working on phase 2 clinical trial of LYS228 against complicated urinary tract infections and complicated intra-abdominal infections. The work on anti-dengue drugs and anti-malaria drugs (KAF156 and KAE609) were already in pipeline.
Boston-based Vertex Pharmaceuticals has more than doubled their research facility in San Diego where they first discovered their key Cystic Fibrosis Drug adding more than 90000 sq ft. to it. The total facility will be now 170,000 sq. ft improving the pharma giant's capability to achieve the next generation of blockbusters.
Los Angeles-based Cedars –Sinai Medical center and UCLA experimenters are describing that a (consumer-grade) Fitbit tracker can be used in some Remote patient Monitoring programs if health professionals know the clinical limitation of the mobile health wearables. The researchers outlined the 90-day study and concluded that the Fitbit data could be used to identify trends that call for health professional involvement
AiCuris along with Prof. Dr. Dr. H.C. Waldmann, Director of the Chemical Biology Department at MPI, will jointly investigate and optimize antibacterial or antiviral compounds, which could be developed into anti-infective drugs.
The University Of Kansas Medical Center is partnering with Garmin Health to foster innovation and better understand on how healthcare wearables can help in the detection and management of significant medical conditions. Their first research will focus on cardiac care and sleep apnea.
Researchers from the University of Wisconsin-Madison have detailed a wearable device that can better measure muscle-tendon tension during certain activities, such as walking or running.
Novartis is launching an mHealth app on Apple's ResearchKit platform to determine whether smartphones are reliable enough for use in ophthalmology studies.
Bristol-Myers Squibb Company and the Harvard Fibrosis Network of the Harvard Stem Cell Institute today announce a research collaboration to discover and develop potential new therapies for fibrotic diseases, including fibrosis of the liver and heart. The Harvard Fibrosis Network brings together researchers across the schools and affiliated hospitals of Harvard University.
The research compared patient care metrics at hospitals that had experienced a data breach and those that had not. For instance, the study examined the proportion of heart attack patients that die within 30 days of being admitted to a health system.
A wearable device, developed by researchers at the GI Innovation Group out of the University of California San Diego, can track electrical activity in the stomach over a 24-hour period. The device works similarly to how an ECG would work for the heart, but instead it monitors the electrical activities of gastrointestinal tract.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.